- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02246049
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (QUATTRO)
A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer
Visão geral do estudo
Status
Condições
Descrição detalhada
This is a single-arm, multicentre phase II study evaluating the efficacy and safety of Bevacizumab (BV) in combination with oxaliplatin, irinotecan hydrochloride, fluorouracil, and leucovorin calcium regimen ( FOLFOXIRI +BV ; Falcone et al. ASCO2013) as first-line treatment for Japanese metastatic colorectal cancer patients.
This study is composed two steps because of collecting safety issue in Japanese patient.
As First step (Step 1), It assess on the initial safety information in ten Japanese patients of the end of 2nd cycle. it is evaluated by DMC.
In parallel with the confirmation of the initial safety issue, register up to 65 cases in total and Step 1 patient, to evaluate the efficacy and safety (Step2).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Tokyo
-
Shinjuku, Tokyo, Japão, 162-0814
- EPS Corporation
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Written Informed consent.
- Histopathologically proven diagnosis of colorectal cancer (adenocarcinoma) excluding vermiform appendix cancer and proctos cancer.
- Not resectable metastatic colorectal cancer
- Age at enrollment is >= 20 and <= 75 years
- ECOG PS < 2 if age < 70 years, ECOG PS = 0 if age = 71-75 years
- One or more measurable lesion in RECIST ver.1.1 criteria according to contrast enhanced CT chest / abdomen / pelvis diagnosis.
- Not previously treated with chemotherapy. ( Previous adjuvant by fluoropyrimidine monotherapy is allowed if more than 24 weeks have elapsed between the end of adjuvant therapy and first relapse.)
Vital organ functions (listed below) are preserved within 2 weeks prior to entry. Data recorded nearest to the entry should be referred. Blood transfusion or erythropoiesis stimulating agents less than 2 weeks prior to the tests are not allowed.
Neu. >= 1,500/cubicmillimeter Pt. >= 100,000/cubicmillimeter Hb. >= 9.0 g/dL T-bil. <= upper limit of normal (ULN)*1.5 AST and ALT,ALP <= upper limit of normal (ULN)*2.5 (<= ULN*5 in case of liver metastasis) Serum creatinine <= upper limit of normal (ULN) *1.5 PT-INR < 1.5 Proteinuria <= 2+
- UGT1A1 genotype tested. Categorized into Wild or single Hetero.
Exclusion Criteria:
- Previously treated with irradiation to bone marrow constituting 20% or more of irradiation field.
- Untreated brain metastases or spinal cord compression or primary brain tumors.
- History of CNS disease.[except for asymptomatic Lacunar stroke]
- Requiring chronic systemic corticosteroid treatment.
- Current or recent ongoing treatment with anticoagulants.
- Clinically significant cardiovascular disease for example cerebrovascular accidents, myocardial infarction, unstable angina, congestive heart failure, serious cardiac arrhythmia requiring medication.
- Treatment with any investigational drug within 4 weeks.
- Patient with Uncontrolled hypertension, Uncontrolled diabetes, Uncontrolled diarrhea, >=grade 1 peripheral neuropathy, Active peptic ulcer, Non-healing wound, Clinically important diseases.
- Major surgical procedure within 28 days prior to study treatment start, open biopsy, or significant traumatic injury, or anticipation of the need for major surgical procedure.[except for implantation of central venous catheter and port system.]
- Lack of physical integrity of the upper gastrointestinal tract.
- Pregnant women, lactating woman , positive by pregnancy test , wishing to become pregnant, and Sexually active males.
- Hepatitis B or hepatitis C. Evidence of HIV infection.
- Previous Chemotherapy for other organs.
- Other active co-existing malignancies.
- History / Presence of thrombosis within 1 year requiring medication.
- History / Presence of paralytic ileus, obstruction or gastrointestinal perforation.
- Malignant coelomic fluid required drainage.
- History of allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications.
- History of fluoropyrimidine severe side effects caused by DPD defect.
- Interstitial pneumonitis or pulmonary fibrosis.
- Evidence or requiring systemic treatment for Infectious disease.
- Patient who is judged by the investigator to be inappropriate for study participation for any reason.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: FOLFOXIRI plus bevacizumab
Induction therapy is followed by the maintenance therapy. [Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. [Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. |
Dado IV
Outros nomes:
Dado IV
Outros nomes:
Dado IV
Outros nomes:
Dado IV
Outros nomes:
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS) at 10 months
Prazo: PFS rate at 10 months from study entry
|
PFS by investigator-reported measurements according to CT image. PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause. PD was defined as Overall Response by RECIST criteria v1.1 according to CT image. |
PFS rate at 10 months from study entry
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Response rate (RR) by central review.
Prazo: Up to 18 months
|
Response evaluation was performed according to RECIST criteria v1.1.
|
Up to 18 months
|
|
Response rate (RR) by investigator-reported measurements.
Prazo: Up to 30 months
|
Response evaluation was performed according to RECIST criteria v1.1.
|
Up to 30 months
|
|
PFS by central review according to CT image.
Prazo: Up to 18 months
|
PFS was calculated from the day of treatment start to the first observation of progression disease (PD) or death from any cause.
|
Up to 18 months
|
|
Overall survival (OS)
Prazo: Up to 30 months
|
OS was calculated from the day of registration in this study to death from any cause.
|
Up to 30 months
|
|
Efficacy by RAS status ; RR,PFS,OS
Prazo: Up to 30 months
|
RR,PFS,OS according to tumor RAS status.
|
Up to 30 months
|
|
Incidence of adverse events
Prazo: Up to 30 months
|
Adverse events were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
All adverse events was collected in duration from starting treatment to whichever shorter "after 30 days from withdrawal treatment" or "later treatment was started".
|
Up to 30 months
|
|
Time to treatment-failure
Prazo: Up to 30 months
|
Up to 30 months
|
|
|
Completion rate in Induction treatment
Prazo: Up to 30 months
|
Up to 30 months
|
|
|
Relative Dose Intensity
Prazo: Up to 30 months
|
Up to 30 months
|
|
|
Treatment duration
Prazo: Up to 30 months
|
Up to 30 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Takeshi Kato, M.D., Ph.D, Department of Surgery, National Hospital Organization Osaka National Hospital.
- Investigador principal: Akiyoshi Kanazawa, M.D., Ph.D, Department of Surgery, Shimane Prefectural Central Hospital.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias
- Neoplasias por local
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Doenças do cólon
- Doenças Intestinais
- Neoplasias Intestinais
- Doenças retais
- Neoplasias Colorretais
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes de proteção
- Inibidores da Topoisomerase
- Agentes Antineoplásicos Imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Micronutrientes
- Vitaminas
- Hormônios e Agentes Reguladores de Cálcio
- Inibidores da Topoisomerase I
- Antídotos
- Complexo de Vitamina B
- Fluorouracil
- Oxaliplatina
- Bevacizumabe
- Leucovorina
- Irinotecano
- Cálcio
- Levoleucovorina
Outros números de identificação do estudo
- QUATTRO
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .